HLA-typed human primary cells

Human leukocyte antigens (HLA) are cell surface proteins that regulate the immune system. HLA genes are extremely diverse, with over 2000 HLA class I alleles and over 600 HLA class II alleles¹. A specific HLA type can be associated with an autoimmune disease² or serve as a biomarker³ to show how cells respond to cancer treatments. They have also become important in understanding the role of the immune system in autoimmune diseases, defense against infections⁴, and personalized medicine⁵.

Unlike animal models, HLA-typed cells provide an optimal platform to test tumor-reactive T-cells in a culture that represents the human system. With the rapid development of personalized cancer immunotherapies such as adoptive cell therapy, custom HLA-typed cells are becoming increasingly important for the development and testing of new drug.

What we offer

We offer a broad range of high-quality HLA-typed cells from several organs, allowing you to test potential therapies and detect cross-reactivity.

With more than 100 HLA-typed donors in stock, we provide a complete HLA typing certificate for each donor — so that you can stop spending valuable time on primary cell typing.

What we provide

• HLA-typed human primary cells and peripheral blood mononuclear cells (PBMC) from a pre-screened donor.
• A complete certificate including 4-digit resolution typing for HLA-A, -B, -C, -DPA1/DPB1, -DQA1/DQB1, and -DRB1/DRB345.
• Multiple cell types from matched donors depending on your needs.
• Only receive the cells you wish to work with — no negative testing is required.

Your benefits

• Minimize off-target interactions preclinically by testing translatability in a human cell setting.
• Translatable results, overcoming the need for animal experiments to develop and test new drugs.
• The HLA typing report provides certainty on the type you need, so you don’t have to do further screening.
• Faster testing, making the development of new cancer therapies more cost-effective and resource-saving.
• Cross-reactivity testing of new therapies in multiple systems using our HLA-typed cells from the lung, kidney, or cardiovascular system.

Contact us for more information

What is HLA nomenclature?

Learn how to decode standardized HLA nomenclature:

View the HLA nomenclature guide

References

Expand

1. Robinson, J., Mistry, K., McWilliam, H., et al. The IMGT/HLA database, Nucleic Acids Research, Volume 39, Issue suppl_1, 1 January 2011, Pages D1171–D1176, doi.org/10.1093/nar/gkq998
2. Liu B, Shao Y, Fu R. Current research status of HLA in immune-related diseases. Immun Inflamm Dis. 2021; 9: 340–350. doi.org/10.1002/iid3.416
3. Jiang, C.Y., Zhao, L., Green, M.D. et al. Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer. Sci Rep 14, 345 (2024). doi.org/10.1038/s41598-023-48546-y
4. Augusto, D.G., Murdolo, L.D., Chatzileontiadou, D.S.M. et al. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature 620, 128–136 (2023). doi.org/10.1038/s41586-023-06331-x
5. Singer, J., Lewitzky, S., Leroy, E. et al.A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet42, 711–714 (2010). doi.org/10.1038/ng.632